P
ELTX icon

&Partners’s Elicio Therapeutics ELTX Stock Holding History

&Partners’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$107K Hold
10,000
– – ﹤0.01% 2336
2025
Q4 		$79.6K Hold
10,000
– – ﹤0.01% 2226
2025
Q3 		$109K Hold
10,000
– – ﹤0.01% 2045
2025
Q2 		$77.2K Buy
+10,000
New +$62.2K ﹤0.01% 1937

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

&Partners's ELTX Position: Q1 2026 in Review

&Partners held its Elicio Therapeutics (ELTX) position steady in Q1 2026 at 10,000 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #2336.

&Partners first reported a position in ELTX in Q2 2025 and has held it in 4 quarters since. The position peaked at $109K in Q3 2025. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

  • &Partners held 10,000 shares of Elicio Therapeutics worth $107K as of Q1 2026.
  • &Partners left its Elicio Therapeutics share count unchanged in Q1 2026.
  • Elicio Therapeutics made up ﹤0.01% of &Partners's portfolio in Q1 2026, its #2336 holding.
  • &Partners first reported a position in Elicio Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • &Partners's Elicio Therapeutics position peaked at $109K in Q3 2025.
  • 47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.